Being the ultimate travel companion of a patient with uterine leiomyosarcoma

Future Oncol. 2022 Sep;18(29s):17-23. doi: 10.2217/fon-2022-0637. Epub 2022 Sep 28.

Abstract

Uterine fibroids are difficult to distinguish from malignant masses using standard ultrasonography; and morcellation carries the risk of disseminating occult cancer in a small but relevant group of women with an undetected uterine malignancy. In this context, we follow the progress of a woman diagnosed with uterine leiomyosarcoma after suboptimal initial surgery for an assumed fibroid. Evidence is reviewed that guided multidisciplinary tumor board decisions about optimal management approaches after local seeding and development of distant metastases, and informed treatment selection at each line of therapy. As the case study illustrates, choice of treatment for advanced soft tissue sarcomas frequently involves finding an appropriate balance between the efficacy and toxicity of available options, aiming to allow patients to maintain their normal lives.

Keywords: doublet toxicity; morcellation; trabectedin; uterine leiomyosarcoma; uterine myomas.

Publication types

  • Review

MeSH terms

  • Female
  • Humans
  • Hysterectomy
  • Laparoscopy*
  • Leiomyoma* / diagnosis
  • Leiomyoma* / pathology
  • Leiomyoma* / surgery
  • Leiomyosarcoma* / diagnosis
  • Leiomyosarcoma* / surgery
  • Morcellation* / adverse effects
  • Uterine Myomectomy*
  • Uterine Neoplasms* / diagnosis
  • Uterine Neoplasms* / pathology
  • Uterine Neoplasms* / therapy

Grants and funding